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Summary
Background: Helicobacter pylori (Hp) infection represents a crucial factor in pathogenesis of gastric cancer
(GC). Factors emanating from bacterium as well as from environmental contributions such as
salt diet and inadequate supply of antioxidants, affect the risk for GC development.
Results: Atrophic gastritis is considered to be a precursor lesion of intestinal type GC that is accompa-
nied by hypergastrinemia with subsequent induction of cyclooxygenase-2 (COX-2), whose
products are responsible for slowing apoptosis and for angiogenesis in GC tumor. The
involvement of proinflammatory cytokines (especially IL-1 and IL-8) and reactive oxygen
species (ROS) due to NFκB activation, increased cell proliferation combined with inhibition of
apoptosis as well as upregulation of peroxisome proliferation activated receptor gamma
(PPARγ) and inducible nitric oxide synthase (iNOS) appear to be major molecular biology
alterations in pathogenesis of GC.
Conclusions: These results suggest the therapeutic usefulness of inhibitors of gastrin expression and release
such as powerful somatostatin analogs (Sandostatin) or blockers of COX-2 (coxibs) in the con-
trol of GC development and progression as chemopreventive agents. Comparative genomic
and proteomic is the key in identifying biomarkers in host and bacterium for the prediction of
gastric cancer in Hp-infected patients.
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HELICOBACTER PYLORI INFECTION AND CORREA CASCADE IN
DEVELOPMENT OF GASTRIC CANCER
Helicobacter pylori (Hp) is the major environmental con-
tributory factor in the development of gastric cancer (GC)
which still remains a major health problem worldwide.
Almost 10 years ago, Hp was classified by the World
Health Organization (WHO) as a group 1 carcinogen [1].
Support for this view has been mainly provided by epi-
demiological studies. A number of studies including our
own showed that the prevalence of Hp and CagA in GC
patients is much higher than in age- and gender-
matched controls [2,3] (Figures 1 and 2). Individuals with
previous Hp infection have significantly increased risk of
GC (4 to 6 folds) [4,5] and the risk of development of GC
is clearly related to the CagA expression of Hp and the
duration of Hp infection accounting in part for the
increasing rates of GC in older individuals [3,6]. There is
also significant geographic relation between GC mortality
rates and the Hp prevalence [7]. Countries with
increased Hp prevalence exhibit also higher rates of GC
and the decline in the GC involving antrum during last
century (see Figure 1) concerns predominantly those
parts of the world in which the rate of Hp prevalence is
also declining (Figure 3). The only exception, that seems
to confirms the above-mentioned rule, is Africa, where
despite high Hp prevalence, the rate of GC remains low,
so called ‘African Enigma’. The high parasite infestation
and ingestion of plant food with higher content of antiox-
idants in this part of the world may somehow protect the
stomach from development of GC. Also in our country, in
the region of the highest (almost 100%) Hp infection rate,
among Tatra Mountain shepherds and their families [8],
the rate of GC appears quite low. This phenomenon
could, however, be explained by the overuse of certain
alcoholic beverages, especially red vines (‘Grzaniec góralski‘
– hot punch) with spices, possessing anti-Hp effects due
to their phenolic compounds [9] exhibiting antioxidant,
cancer suppressing and stimulating effect on the synthe-
sis of nitric oxide, which has been shown to protect the
mucosa against damage and to stimulate the mucosal
repair and healing of mucosal inflammation, erosions
and ulcerations [10].
On the other hand, despite an assumption that Hp infec-
tion plays a crucial role in the pathogenesis of GC, only a
small proportion (1–2%) of infected patients develop GC
(see Figure 3). Thus, the Hp infection may be neither
essential nor wholly responsible for the process of malig-
nant transformation. In fact, the majority of Hp infected
patients does not develop GC, while a number of Hp-
seronegative patients do develop GC (up to 20%).
Therefore, in addition to Hp other environmental and
host factors must be important [11]. According to our
experience following the occurrence of gastric atrophy,
usually the Hp detection becomes difficult despite of the
obvious premalignant changes in the gastric mucosa.
Simply the Hp disappears from the stomach with
marked atrophic changes perhaps due to lack of nutri-
ents for this germ. In addition, as shown recently by
Semino-Mora et al. [12], bacteria may hide themselves
within the mucosal cells without causing alterations in
Figure 1.
Anti-Hp IgG seropositivity in GC
patients and age- and gender-
matched controls in various age
groups. According to our obser-
vations, there is a tendency of Hp
infection to decline during last
decade combined with the fall in
the occurrence of GC at the distal
part of the stomach, while at the
same time there is an increase of
GC at the proximal portion of the
stomach.
SR67
Med Sci Monit, 2003; 9(7): SR65-78 Konturek PC et al – H. pylori infection, atrophic gastritis, cytokines, gastrin…
SR
immunological system (Hp serology negative) and with-
out producing urease in the gastric lumen so that the
urea breath test detecting active Hp infection becomes
negative.
There is little doubt that, at least one type of tumor, gas-
tric lymphoma of mucosa-associated lymphoid tissue
(MALT lymphoma) is causally related to Hp infection as it
is acquired in gastric mucosa almost in 100% in association
with Hp infection. Clinical studies have shown that the
eradication of bacterium, at least from early lesions, results
in tumor regression in 60 to 92% [14,15] (Figure 4)
From pathological point of view, the development of
intestinal-type GC involves progression through a well-
defined series of histological steps, initiated by the
change of normal mucosa to chronic superficial gastritis,
followed by the appearance of atrophic gastritis and
intestinal metaplasia, then dysplasia and finally adeno-
carcinoma preceded and accompanied by numerous
changes in molecular biology of mucosa cells, particular-
ly in the regeneration zone of gastric glands from which
all types of GC originate (Figure 5). These subsequent
pathological changes from gastritis to gastric dysplasia
and GC was recognized by Correa [2] long before the
Hp was discovered as major gastric pathogen by
Marshall and Warren [13,14] and this sequence is called
‘Correa’s cascade’. Following discovery of Hp, Correa
included this pathogen in his cascade and ascribed to it
the major role in GC pathogenesis (Figure 5 and 6).
It is now clear that patients with pangastritis are prone
to the development of gastric atrophy and progression
to GC. In contrast, gastritis predeminantly located in
antrum (antrum-predominant gastritis) that is associated
with hypergastrinemia and hyperchlorhydria may result
in duodenal ulcerations that somehow ‘protect’ the
stomach from development of GC (Figure 7). In con-
Figure 2.
CagA Hp IgG seropositivity in GC
patients and age- and gender-
matched controls in the various
age groups.
Figure 3.
Hp prevalence in populations in
various parts of the world and
related consequences of Hp
infection including GC (on the
right). Discoverers of Hp in
humans [13,14] (on left).
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Figure 4.
Prevalence of Hp and CagA
seropositivity in low-grade gas-
tric MALT-lymphoma (on left)
and the regression of MALT
tumor following eradication of Hp
(on right).
Figure 5.
Molecular basis of gastric 
cancerogenesis.
Figure 6.
Modified Correa’s cascade with
inclusion of Hp infection in gas-
tric cancerogenesis.
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trast, ‘corpus-predominant gastritis’, though similarly
accompanied by hypergastrinemia due to decrease of
gastric acid and the removal of acid-controlled suppres-
sion of antral somatostatin, tends to progress into meta-
plasia, atrophy, dysplasia and GC [14,15]. The strongest
evidence for the association between Hp infection and
GC development was provided by the prospective study
of Uemura et al. [16] (Figure 8). In this study a large
number of patients with Hp infection were followed
with serial endoscopic examinations. Over time, GC was
not diagnosed in Hp negative patients or in patients
who had duodenal ulcer. In contrast, the risk for GC
was highly increased in Hp positive patients with gastric
ulcers, hyperplastic polyps and non-ulcer dyspepsia.
Uemura and Okamoto [17] revealed that in patients
with early GC subjected to endoscopic mucosal resection
but without Hp therapy, new GC was found in 13% as
opposed to only 1% on GC relapse during 4–7 years in
similar group of patients subjected to GC mucosectomy
combined with eradication of Hp. The difference in GC
occurrence between eradication group (N=65) and
non-treated group (N=67) was highly significant. It is of
interest that such eradication in early GC group was fol-
lowed by the improvement of gastric acid secretion,
remission of corpus-gastritis and decrease of nitroso com-
pounds associated with gastric carcinogenesis. These
studies indicate that Hp positive GC patients should be
eradicated even before the surgery to reduce the pro-
gression of ongoing gastric carcinogenesis.
MICROBIAL AND HOST FACTORS IN CANCER DEVELOPMENT
It appears that increased risk for the development of
GC in Hp infected patients depends on both microbial
and host factors (Figure 9). Among microbial factors,
especially the gene expression for Cag pathogenicity
island (PAI) (a large region of the genome containing
approximately 30 genes), is an important determinant
of GC development in Hp infected patients. Some of the
genes of the Cag PAI have close similarities to a type IV
Figure 7.
Ulcerogenic or cancerogenic
action of Hp infection depends
upon the localization of the infec-
tion. Antrum-predominant gastri-
tis leads to duodenal ulcer via
increased gastrin release and
gastric acid hypersecretion, while
corpus-predominant gastritis
results in gastric atrophy with
gastric ulcer, MALT lymphoma or
GC.
Figure 8.
Results of prospective studies of
Uemura et al. [16] on effects of
prolong Hp infection on develop-
ment of GC in patients with duo-
denal ulcerations, hyperplastic
polyps, gastric ulcers or non-
ulcer dyspepsia.
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secretion system [18]. This system provides the mecha-
nisms for a direct transfer of bacterial cytotoxic protein
into eucaryotic host cells. The CagA was shown to be
translocated from adherent bacterial cell to epithelial
cell. This leads to phosphorylation of CagA on the tyro-
sine residue by cellular kinases. This induces cell mor-
phological changes including actin polymerization and
pedestal formation, possible by activating N-WASP. It
may also trigger a signaling cascade via MAP pathway,
which may induce the transcription of nuclear genes
[19] (Figure 10). It is postulated that CagA by still not
completely unclair mechanisms activates NFκB signal-
ing system leading to the increased production of
cytokines such as IL-8. It is possible that increased IL-8
may result in a greater degree of gastritis, ultimately
predisposing to the development of GC [20,21], but
exact mechanism involved in CagA-IL-8 promotion of
cancerogenesis remains to be elucidated, but there is lit-
tle doubt that CagA positive Hp infection remarkably
raises the risk of GC (see Figure 2). Another important
virulence factor is a vacuolating cytotoxin (VacA) [22]. A
vacA gene is present in virtually all of the Hp strains
examined. However, strains vary considerably in the
production of vacuolating cytotoxin. This is attributed
to the variation in vacA gene structure. Also factors
responsible for the attachment of Hp to gastric epitheli-
um (blood group antigen binding adhesin BabA encod-
ed by babA or sialic acid binding adhesin) are important
microbial factors associated with an increased risk for
GC development [21,22].
Concerning the host answer, a multiple pathways are
involved in the gastric carcinogenesis including chronic
inflammatory response with predominant lymphocyte
Th1 answer, increased cell proliferation due to activa-
tion of protooncogenes, increased expression of mucos-
al growth factors and hypergastrinaemia with overex-
pression of COX-2. Finally, polymorphisms of host
Figure 9.
Mucosal lesions depends upon
the virulence of Hp and immuno-
logical conditions of host.
Figure 10.
Genes of Cag pathogenicity
island encodes type IV secretion
system which provides the
mechanism for direct transfer of
bacterial effector protein (cyto-
toxins) into eucaryotic host
mucosal cell (Covacci and
Rappuoli, 2000).
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genes for inflammatory cytokines such as IL-1β and
TNFα [23] and excessive production of prostaglandins
(PG) and upregulation of PPARγ (with subsequent alter-
ation in apoptosis lead to GC development (Figure 11)
COX-2 EXPRESSION IN DEVELOPMENT OF GASTRIC CANCER
AND THERAPEUTICAL PROPOSAL
The increased expression of mitogenic metabolites of
arachidonic acid such as PG due to COX-2 overexpres-
sion in gastric mucosa during Hp infection could repre-
sent an important link between Hp-induced gastritis
and gastric carcinogenesis (Figure 12). Our previous
studies demonstrated a significant upregulation of
COX-2 expression at the mRNA and protein level in Hp
infected gastric mucosa [23]. The procarcinogenic
actions of COX-2-derived PG stimulated by Hp (Figure
13) include the stimulation of cell proliferation, the inhi-
bition of apoptosis, the induction of angiogenesis and
the direct mutagenic effect [25] (Figure 14).
The involvement of COX-2 overexpression in gastric
carcinogenesis suggests that COX-2 blockade might be
useful in chemoprevention against gastric cancer. Our
recent human study performed in GC patients showed
that 14-day treatment with selective COX-2 blocker
resulted in a significant decrease in plasma and tumor
contents of both amidated gastrins and their precursor,
progastrin [25]. This treatment led also to significant
upregulation of caspase-3 mediating apoptotic cell
death [25,26]. Our recent studies suggest that applica-
tion of somatostatin and its powerful analog such as
Sandostatin Lar (Novartis, Pharma), suppresses the
COX-2 expression and reduces the generation of gas-
trin by cancer cells, thus slowing down the tumor
growth and metastatses [26] (Figure 15). This therapeu-
tical approach may not only be applicable to hypergas-
trinemic cancers such as gastrinoma but also to ordinary
GC expressing progastrin and its products, amidated
gastrins, the most potent inducers of COX-2 in GC
tumor and surrounding gastric mucosa infected with Hp.
Figure 11.
Development of GC depends
upon the interaction of microbial
and host factors.
Figure 12.
COX-2 immunostaining in Hp-
induced atrophic gastritis, intesti-
nal metaplasia and GC tissue of
intestinal or diffuse type.
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Figure 13.
Arachidonic acid metabolism and
its products through the action of
COX-1 and COX-2.
Figure 14.
Biological action of COX-1 and
COX-2 metabolites.
Figure 15.
Inhibition of COX-2 l by
Rofecoxib (Vioxx) leads to upreg-
ulation of COX-2 and induction of
apoptosis in GC, while reducing
the tumor size and angiogenesis.
Administration of Sandostatin Lar
(Novartis) results in the attenua-
tion of COX-2 expression and the
fall in gastrin production by GC
tumor.
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Among the growth factors, gastrin appears to be one of
the most important gastrointestinal hormones involved
in the physiological stimulation of cell proliferation at
regeneration zone of glands in the oxyntic and colon
mucosa and in tumor tissue (Figure 16). Hp infection in
gastric mucosa is associated with increased plasma gas-
trin release, originating from the action on G-cells or
cancer cells of N-α methyl-histamine (NαMH) released
by Hp, a potent gastrin-releasing substance in Hp-
infected stomach (Figure 17). Also proinflammatory
cytokines are known to stimulate gastrin expression and
release in GC (Figure 18). The previous studies have
shown that gastrin after binding to its receptor (CCKB-
R) activates the cascade of phosphorylation reaction
which targets ERKs (Extracellular Signal-Regulated
Kinases) via both protein kinase C-dependent and
C–independent pathways. The ERKs in turn appear to
activate early response of genes such as c-fos or c-jun
which appears to be essential for activation of cell prolif-
eration [27–29].
In our earlier studies we demonstrated in GC signifi-
cantly increased gastrin levels in serum, gastric juice
and GC tissues. We demonstrated for the first time the
presence of gastrin immunoreactivity and gastrin
immunostaining in GC biopsy samples [30–32]. More
importantly, the gene expression for gastrin receptor
(CCKB-R) was detected in GC tissue (Figure 19). This
indicates that gastrin produced in excessive amounts in
GC tumor stimulates the tumor growth by autoregula-
tive mechanism [32]. In addition, Hp infection may
result in the upregulation of gene expression of certain
growth factors such as EGF or HGF, that were found to
decline following the eradication of Hp [31,32].
Figure 16.
Production of gastrin in G-cells of
antral mucosa and the precur-
sors of gastrin; pre-progastrin
and progastrin and Gly-Gly-
extended gastrin. The latters are
Involved in gastric and colorectal
carcinogenesis.
Figure 17.
Hypergastrinemia and duodenal
ulcers in gastrinoma patients (on
left) and role of gastrin and COX-
2 in Hp-induced gastric carcino-
genesis (on right).
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The precise mechanism by which gastrin promotes gas-
tric carcinogenesis remains still unclear. Our recent in
vitro study using gastric cancer cell line confirmed that
gastrin stimulates strongly the expression of HGF, an
important mucosal growth factors, and COX-2 that
inhibits cell apoptosis [32]. Furthermore, we found that
exogenous gastrin has a stimulatory effect on the
expression of antiapoptotic BCl-2 and survivin, which
play a critical role in the regulation of apoptosis as
important antiapoptotic proteins [32]. These data indi-
cate that gastrin has stimulatory effect on cancer cell
proliferation and concurrently shows antiapoptotic
activities (Figure 20). These results suggest that the
reduction in gastrin gene expression and subsequent
suppression of its enhancing action on COX-2 expres-
sion, using inhibitor of gastrin release such as powerful
Figure 18.
Crucial role of gastrin in gastric
carcinogenesis via direct stimula-
tion of the proliferation of cancer
cells, COX-2 induction with sub-
sequent angiogenesis, anti-apop-
tosis and cell cycle dysregula-
tion.
Figure 19.
Gene expression of gastrin and
its receptors (CCKB-R) in gastric
antrum and corpus as well as in
the intestinal and diffuse types
GC cells.
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somatostatin analog (octeotride) combined with the
attenuation of expression of COX-2 by specific blockers
‘coxibs’ may be fully justified as another therapeutical
approach in the control of progression of GC. Attempts
to immunoneutralize gastrins produced by gastric or
colorectal cancer using ‘vaccination’ with G-17 com-
plexed with Diphterium toxin resulted in only small
increase of the survival of patients with advanced GC or
colorectal cancers [33]. We found that failure could be
due to the immunoneutralization of only one species of
gastrin, namely G-17, while others including G-34 and
progastrin (involved in stimulation of cancer cell
growth) remained unaffected (Figure 21). Further
attempts to use similar ‘gastrimmune’ but directed
against major types of gastrin species overproduced in
GC or colorectal cancer may provide new tool for sup-
pressing gastrins playing crucial role in cancerogenesis
in the stomach and colon.
PPARS AND CANCER GROWTH – POSSIBLE THERAPEUTIC
IMPLICATIONS
The peroxisome proliferator-activated receptors (PPARs)
represent a family of nuclear receptors that are closely
related to thyroid hormone or retinoid receptors. Three
PPAR subtypes (PPARα, PPARδ, PPARγ) have been iden-
tified so far [34]. However, PPARγ is the most extensively
studied of the three PPAR subtypes to date. Upon ligand
binding, PPAR activates the transcription of many PPAR
responsive genes involved in the regulation of adipocyte
differentiation, the enhancement of target tissues to
insulin, the inflammation, the carcinogenesis and the cell
cycle control [35] (Figure 22). Recently, the increase in
PPARγ expression parallel to COX-2 overexpression was
found in the gastric mucosa of Mongolian gerbils infect-
ed with Hp which is accepted as the best animal model
for Hp-induced gastric carcinogenesis [35] (Figure 22).
In addition to these data, Takahashi et al. [36] observed
Figure 20.
Effect of increasing concentra-
tions of gastrin (G-17) on gene
expresson of COX-2, HGF, and
apoptosis regulating proteins
(Bax, Bcl-2, Survivin) in isolated
gastric cancer cells [30].
Figure 21.
The influence of ‘vaccination’
with complex of G-17 +
Diphterium toxoid ‘Gastrimmune’
on plasma levels of gastrin-17
(G-17) and combination of G-17
+ G-34 of 10 patients with
advanced colorectal cancer and
hypergastrinemia before and after
meat-meal feeding (unpublished
data).
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a pronounced inhibition of cell growth and induction of
apoptosis in human gastric cancer cells. These data indi-
cates that the PPARγ ligands may have potential as
chemotherapeutic agents for treatment of GC but this
option has not been explored [36].
INDUCTION OF NITRIC OXIDE SYNTHASE (INOS) AND GASTRIC
CANCER (GC)
Current information suggests that nitric oxide (NO) may
contribute to carcinogenesis representing an important
link between chronic inflammation and gastric carcino-
genesis. The postulated role of NO in carcinogenesis
involves modulation of transcription factors (NFκB, AP-1
pathways etc), direct oxidative DNA damage, stimulation
of angiogenesis, inhibition of DNA repair enzymes, dys-
regulation of apoptosis and activation of oncogene
expression [37]. The recent paper by Touati et al. [38]
demonstrated a direct gastric mutagenic effect due to
Hp infection in the Big Blue transgenic mouse model.
This effect was associated with a 5-fold increase in the
expression of iNOS [37,38]. In accordance to these data
we found recently a significant elevation of iNOS expres-
sion in the biopsy taken from gastric cancer as compared
to non-cancerous gastric mucosa (Figure 24).
CONCLUSIONS
In conclusion, Hp infection represents one of the major
gastric carcinogens. Factors emanating from host, bacteri-
um and other environmental factors influence the risk for
GC development in atrophic gastric mucosa. The molecu-
lar mechanisms of gastric carcinogenesis are complex and
involve increased production of proinflammatory
cytokines and reactive oxygen species due to NFκB activa-
tion, increased cell proliferation and inhibition of apopto-
sis caused by hypergastrinaemia and activation of pro-
tooncogenes, alterations in epithelial cell growth due to
overexpression of gastrin and its receptors, COX-2,
PPARγ and iNOS. Each of these factors involved in gastric
Figure 22.
Activation of PPAR(by specific 
ligands results in alteration of
gene expression of substances
involved in cell cycle control, car-
cinogenesis, inflammation and
lipid-glucose metabolism.
Figure 23.
Role of nitric oxide in gastric car-
cinogenesis. Expression of iNOS
mRNA in the gastric cancer tis-
sue (line 2) and non-tumorous
adjacent gastric mucosa (line 1)
and non-infected normal gastric
mucosa (line 3).
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ulcerogenesis may serve as cancer biomarkers and repre-
sent potential target of chemoprevention (Figure 25).
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